AlloVir’s $276.25 Million Initial Public Offering


Latham & Watkins LLP represented the underwriters in the offering.

AlloVir, Inc., a late clinical-stage cell therapy company, has announced the pricing of its upsized initial public offering of 16,250,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.

AlloVir’s common stock started trading on The Nasdaq Global Market on July 30, 2020 under the ticker symbol “ALVR.” All of the common stock is being offered by AlloVir. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AlloVir, are expected to be $276.25 million, excluding any exercise of the underwriters’ option to purchase additional shares.

The offering closed on August 3, 2020, subject to satisfaction of customary closing conditions. AlloVir has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of AlloVir’s common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, SVB Leerink LLC, and Piper Sandler & Co. acted as underwriters for the offering.

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili (Picture), with New York associates Justin McNamee, Patrick Maguire, and Laura Harper.

Involved fees earner: Nathan Ajiashvili – Latham & Watkins; Patrick Maguire – Latham & Watkins; Justin McNamee – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: J.P. Morgan Securities LLC; Morgan Stanley; Piper Sandler; SVB Leerink LLC;

Author: Ambrogio Visconti